Identification

Name
Remoxipride
Accession Number
DB00409  (APRD00316)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.

Structure
Thumb
Synonyms
  • Remoxiprida
  • Remoxipride
  • Remoxipridum
External IDs
A 33547 / A-33547 / FLA 731 / FLA-731(-)
Product Ingredients
IngredientUNIICASInChI Key
Remoxipride hydrochlorideMH4OU8RWCW117591-79-4SPFVHFBNXPARTR-IDMXKUIJSA-N
International/Other Brands
Roxiam
Categories
UNII
0223RD59PE
CAS number
80125-14-0
Weight
Average: 371.269
Monoisotopic: 370.089205259
Chemical Formula
C16H23BrN2O3
InChI Key
GUJRSXAPGDDABA-NSHDSACASA-N
InChI
InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
IUPAC Name
3-bromo-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2,6-dimethoxybenzamide
SMILES
CCN1CCC[[email protected]]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC

Pharmacology

Indication

Remoxipride is an atypical antipsychotic once used for the treatment of schizophrenia.

Structured Indications
Not Available
Pharmacodynamics

Remoxipride, a substituted benzamide, is a selective D2 receptor antagonist. It has been shown to be effective in the treatment of schizophrenia. Some antipsychotics block domapinergic receptors as well as cholinergic, noradrenergic and histaminergic receptors. Remoxipride was developed to act specifically on the dopamine D2 receptor. As a consequence, several undesired side effects can occur. Patients often feel they are not taking any antipsychotic drug. It has a potent affinity for the sigma receptor, but it is unclear whether it is a sigma agonist or antagonist. The contribution of this property to its clinical profile is unknown. Blocking the D2 dopamine receptor is known to cause relapse in patients that have achieved remission from depression, and such blocking also counteracts the effectiveness of SSRI medication.

Mechanism of action

Remoxipride acts as an antagonist at the D2 dopamine receptor. It is believed that overactivity of dopamine systems in the mesolimbic pathway may contribute to the "positive symptoms" of schizophrenia (such as delusions and hallucinations), whereas problems with dopamine function in the mesocortical pathway may be responsible for the "negative symptoms", such as avolition, flat emotional response and alogia. Therefore, by decreasing the levels of dopamine in these pathways, it is thought that remoxipride is able to reduce the symptoms of schizophrenia, particularily the "positive symptoms".

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 2A
other/unknown
Human
USigma non-opioid intracellular receptor 1
antagonist
Human
Absorption

Rapidly absorbed. Absolute bioavailability is 90%.

Volume of distribution
Not Available
Protein binding

89-98%

Metabolism

No active metabolites

Route of elimination
Not Available
Half life

4-7 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineRemoxipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineRemoxipride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineRemoxipride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Remoxipride can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Remoxipride is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Remoxipride.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Remoxipride.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Remoxipride.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Remoxipride can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Remoxipride.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amperozide.Experimental
AmphetamineRemoxipride may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Remoxipride.Approved, Investigational
ArtemetherThe metabolism of Remoxipride can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Remoxipride.Approved
AtomoxetineThe metabolism of Remoxipride can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Azaperone.Investigational, Vet Approved
AzelastineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Remoxipride is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Benzocaine.Approved
BenzphetamineRemoxipride may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Remoxipride is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Remoxipride can be decreased when combined with Betaxolol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Remoxipride.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remoxipride.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Remoxipride.Approved, Investigational
BuprenorphineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Remoxipride can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Remoxipride.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Remoxipride.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Remoxipride.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Remoxipride.Approved
CanertinibThe risk or severity of adverse effects can be increased when Remoxipride is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Remoxipride.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Remoxipride can be decreased when combined with Celecoxib.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Remoxipride.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Remoxipride can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorphenamine.Approved
ChlorphentermineRemoxipride may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Remoxipride can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Remoxipride can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Remoxipride can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Remoxipride can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Remoxipride can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Remoxipride can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clidinium.Approved
ClobazamThe metabolism of Remoxipride can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Remoxipride can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Remoxipride.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Remoxipride can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Remoxipride can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Remoxipride can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Remoxipride can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Remoxipride.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Remoxipride.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Remoxipride.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Remoxipride can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Remoxipride can be increased when it is combined with Darunavir.Approved
DelavirdineThe metabolism of Remoxipride can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Remoxipride.Approved
DesipramineThe metabolism of Remoxipride can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Remoxipride.Approved
DetomidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineRemoxipride may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Remoxipride.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Remoxipride.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Remoxipride is combined with Diethyl ether.Experimental
DiethylpropionRemoxipride may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Remoxipride.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Remoxipride.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Remoxipride can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Remoxipride.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Remoxipride can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Remoxipride is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Illicit
DronedaroneThe metabolism of Remoxipride can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Remoxipride can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Remoxipride is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Remoxipride.Approved, Investigational
EliglustatThe metabolism of Remoxipride can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Remoxipride.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Remoxipride.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Remoxipride.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Remoxipride.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Remoxipride.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Remoxipride.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Remoxipride.Approved
EthanolRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remoxipride.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Remoxipride.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Remoxipride.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Remoxipride can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Remoxipride.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Remoxipride.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Remoxipride.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Remoxipride can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Remoxipride.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Remoxipride.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Remoxipride.Approved, Illicit, Investigational
GepefrineRemoxipride may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Remoxipride can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Hexobarbital.Approved
HydrocodoneRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Remoxipride.Approved, Illicit
HydroxyamphetamineRemoxipride may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Iloperidone.Approved
ImipramineThe metabolism of Remoxipride can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Remoxipride can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Remoxipride is combined with Indiplon.Investigational
Iofetamine I-123Remoxipride may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Remoxipride.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Remoxipride.Approved, Vet Approved
IsoniazidThe metabolism of Remoxipride can be decreased when combined with Isoniazid.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Remoxipride.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Remoxipride can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Remoxipride.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Remoxipride.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Remoxipride.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Remoxipride.Approved, Investigational
LisdexamfetamineRemoxipride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Remoxipride.Approved
LofentanilThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lofentanil.Illicit
LopinavirThe metabolism of Remoxipride can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Remoxipride.Approved
LorcaserinThe metabolism of Remoxipride can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Remoxipride.Approved
LumefantrineThe metabolism of Remoxipride can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Remoxipride.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Vet Approved
ManidipineThe metabolism of Remoxipride can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Remoxipride is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Melperone.Approved, Investigational
MephedroneRemoxipride may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineRemoxipride may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remoxipride.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Meptazinol.Experimental
MequitazineRemoxipride may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Metaxalone.Approved
MethadoneThe metabolism of Remoxipride can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineRemoxipride may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Remoxipride.Approved
MethotrimeprazineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineRemoxipride may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Remoxipride.Approved, Investigational
MetoprololThe metabolism of Remoxipride can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineRemoxipride may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Remoxipride.Approved, Illicit
MidomafetamineRemoxipride may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Remoxipride can be decreased when combined with Midostaurin.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Remoxipride.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Investigational
MirabegronThe metabolism of Remoxipride can be decreased when combined with Mirabegron.Approved
MirtazapineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDARemoxipride may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Remoxipride.Approved
MolindoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Remoxipride.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Remoxipride.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Remoxipride.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Remoxipride.Approved, Withdrawn
NevirapineThe metabolism of Remoxipride can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Remoxipride can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Remoxipride can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Remoxipride.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Remoxipride.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Remoxipride.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Remoxipride is combined with Opium.Approved, Illicit
OrphenadrineRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Remoxipride is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Remoxipride.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Remoxipride.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Remoxipride.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Remoxipride.Approved
PanobinostatThe serum concentration of Remoxipride can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Remoxipride can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Remoxipride can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Remoxipride.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Remoxipride.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved
PerazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Remoxipride.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Remoxipride.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Remoxipride.Approved
PhenibutThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Remoxipride.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenoxyethanol.Approved
PhentermineRemoxipride may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Remoxipride.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pomalidomide.Approved
PramipexoleRemoxipride may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Remoxipride.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Remoxipride.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Remoxipride.Approved, Vet Approved
PromazineThe metabolism of Remoxipride can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Remoxipride is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Remoxipride.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Remoxipride is combined with PSD502.Investigational
PseudoephedrineRemoxipride may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Remoxipride.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Remoxipride.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Remoxipride.Approved
QuinidineThe metabolism of Remoxipride can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Remoxipride can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Remoxipride can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Remoxipride.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Remoxipride.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Remoxipride.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Remoxipride.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ritanserin.Investigational
RitobegronRemoxipride may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Remoxipride can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Remoxipride.Approved
RolapitantThe metabolism of Remoxipride can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Romifidine.Vet Approved
RopiniroleRemoxipride may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Remoxipride.Approved
RotigotineRemoxipride may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Remoxipride.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Remoxipride.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Remoxipride.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Remoxipride can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Remoxipride.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved
StiripentolThe metabolism of Remoxipride can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Remoxipride.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Remoxipride.Approved, Investigational
SuvorexantRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Remoxipride.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Remoxipride.Approved
TerbinafineThe metabolism of Remoxipride can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Remoxipride.Approved
TetracaineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetrodotoxin.Investigational
ThalidomideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Remoxipride can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Remoxipride.Approved
TiagabineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Remoxipride can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tilidine.Experimental
TipranavirThe metabolism of Remoxipride can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Remoxipride.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Remoxipride can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Remoxipride.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Remoxipride.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Remoxipride.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Remoxipride.Approved
VenlafaxineThe metabolism of Remoxipride can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Remoxipride.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Remoxipride is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Remoxipride.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Remoxipride can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Remoxipride.Approved, Investigational
ZolpidemRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Remoxipride.Approved
ZotepineThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Remoxipride.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference
US4232037
General References
Not Available
External Links
Human Metabolome Database
HMDB14553
PubChem Compound
54477
PubChem Substance
46508689
ChemSpider
49195
BindingDB
50026045
ChEBI
92948
ChEMBL
CHEMBL22242
Therapeutic Targets Database
DAP000312
PharmGKB
PA164749051
Wikipedia
Remoxipride
ATC Codes
N05AL04 — Remoxipride

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility74 mg/LNot Available
logP2.10HOEGBERG,T ET AL. 1986
Predicted Properties
PropertyValueSource
Water Solubility0.127 mg/mLALOGPS
logP2.94ALOGPS
logP2.34ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)13.06ChemAxon
pKa (Strongest Basic)8.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.8 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity90.56 m3·mol-1ChemAxon
Polarizability36.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9705
Caco-2 permeable+0.5835
P-glycoprotein substrateSubstrate0.775
P-glycoprotein inhibitor INon-inhibitor0.674
P-glycoprotein inhibitor IINon-inhibitor0.6462
Renal organic cation transporterNon-inhibitor0.5402
CYP450 2C9 substrateNon-substrate0.868
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.5728
CYP450 1A2 substrateNon-inhibitor0.6776
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5505
Ames testNon AMES toxic0.6906
CarcinogenicityNon-carcinogens0.8373
BiodegradationNot ready biodegradable0.9703
Rat acute toxicity2.8267 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.802
hERG inhibition (predictor II)Inhibitor0.7976
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dimethoxybenzenes. These are organic aromatic compounds containing a monocyclic benzene moiety carrying exactly two methoxy groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Methoxybenzenes
Direct Parent
Dimethoxybenzenes
Alternative Parents
3-halobenzoic acids and derivatives / Benzamides / Phenoxy compounds / Anisoles / Benzoyl derivatives / Alkyl aryl ethers / Bromobenzenes / Aryl bromides / N-alkylpyrrolidines / Trialkylamines
show 7 more
Substituents
M-dimethoxybenzene / Dimethoxybenzene / Halobenzoic acid or derivatives / 3-halobenzoic acid or derivatives / Benzamide / Benzoic acid or derivatives / Phenoxy compound / Anisole / Benzoyl / Phenol ether
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Details
1. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  2. Lang AE, Sandor P, Duff J: Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45. [PubMed:8665533]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. D(4) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Seeman P, Corbett R, Van Tol HH: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 1997 Feb;16(2):93-110; discussion 111-35. [PubMed:9015795]
Details
3. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Christian AJ, Goodwin AK, Baker LE: Antagonism of the discriminative stimulus effects of (+)-7-OH-DPAT by remoxipride but not PNU-99194A. Pharmacol Biochem Behav. 2001 Mar;68(3):371-7. [PubMed:11325388]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Seeman P, Corbett R, Van Tol HH: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology. 1997 Feb;16(2):93-110; discussion 111-35. [PubMed:9015795]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Opioid receptor activity
Specific Function
Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma m...
Gene Name
SIGMAR1
Uniprot ID
Q99720
Uniprot Name
Sigma non-opioid intracellular receptor 1
Molecular Weight
25127.52 Da
References
  1. Lang A, Soosaar A, Koks S, Volke V, Bourin M, Bradwejn J, Vasar E: Pharmacological comparison of antipsychotic drugs and sigma-antagonists in rodents. Pharmacol Toxicol. 1994 Sep-Oct;75(3-4):222-7. [PubMed:7800667]
  2. Okuyama S: [Atypical antipsychotic profiles of sigma receptor ligands]. Nihon Yakurigaku Zasshi. 1999 Jul;114(1):13-23. [PubMed:10562961]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 17:35